1
|
Meunier M, Spillmann A, Rousseaux C, Schwamborn K, Hanson M. An oral cholera vaccine in the prevention and/or treatment of inflammatory bowel disease. PLoS One 2023; 18:e0283489. [PMID: 37639428 PMCID: PMC10461820 DOI: 10.1371/journal.pone.0283489] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2023] [Accepted: 08/12/2023] [Indexed: 08/31/2023] Open
Abstract
The oral cholera vaccine WC-rBS consists of 4 different inactivated strains of Vibrio cholerae (LPS source) admixed with recombinant cholera toxin B subunit. Because of its unique composition and anti-inflammatory properties reported for both CTB and low doses of LPS from other Gram-negative bacteria, we speculated that WC-rBS might have anti-inflammatory potential in a chronic autoimmune disease such as inflammatory bowel diseases. First in vitro endotoxin tolerance experiments showed the surprising WC-rBS potential in the modulation of inflammatory responses on both PBMCs and THP1 cells. WC-rBS was further evaluated in the Dextran Sodium Sulfate colitis mouse model. Administrated orally at different dosages, WC-rBS vaccine was safe and showed immunomodulatory properties when administered in a preventive mode (before and during the induction of DSS colitis) as well as in a curative mode (after colitis induction); with improvement of disease activity index (from 27 to 73%) and histological score (from 65 to 88%). Interestingly, the highest therapeutic effect of WC-rBS vaccine was observed with the lowest dosage, showing even better anti-inflammatory properties than mesalamine; an approved 5-aminosalicylic acid drug for treating IBD patients. In summary, this is the first time that a prophylactic medicine, safe and approved for prevention of an infectious disease, showed a benefit in an inflammatory bowel disease model, potentially offering a novel therapeutic modality for IBD patients.
Collapse
Affiliation(s)
| | | | - Christel Rousseaux
- Intestinal Biotech Development, Faculté de Médicine—Pole Recherche, Lille, France
| | | | | |
Collapse
|
2
|
Erlmeier F, Klümper N, Landgraf L, Strissel P, Strick R, Sikic D, Taubert H, Wach S, Geppert C, Bahlinger V, Breyer J, Ritter M, Bolenz C, Roghmann F, Erben P, Schwamborn K, Wirtz R, Horn T, Wullich B, Hölzel M, Hartmann A, Gschwend J, Weichert W, Eckstein M. Spatial immunephenotypes of distant metastases but not matched primary urothelial carcinomas predict response to immune checkpoint inhibition. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)01206-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
3
|
Cox A, Klümper N, Stein J, Sikic D, Breyer J, Bolenz C, Roghmann F, Erben P, Wirtz R, Wullich B, Ritter M, Hölzel M, Schwamborn K, Horn T, Gschwend J, Hartmann A, Weichert W, Erlmeier F, Eckstein M. Intrinsic molecular urothelial cancer subtypes remain stable during metastatic evolution. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)01209-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
4
|
Möller A, Schwamborn K, Spillmann A, Hoogstraate J, Szulkin R, Akre O, Egevad L, Clements M, Aly M. Travel vaccines are strongly associated to reduced mortality in prostate cancer patients - a real effect or residual confounding? Vaccine 2022; 40:3797-3801. [PMID: 35610103 DOI: 10.1016/j.vaccine.2022.05.028] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2021] [Revised: 05/05/2022] [Accepted: 05/08/2022] [Indexed: 10/18/2022]
Abstract
Repurposing of existing drugs and vaccines for diseases that they were not originally intended for is a promising research field. Recently there has been evidence that oral cholera vaccine might be used in the treatment of inflammatory disease and some common cancers. Specifically, Ji et al showed that the administration of cholera vaccine after a prostate cancer diagnosis reduced prostate cancer specific mortality rates by almost 50%. In a cohort of men from Stockholm, Sweden, with more detailed cancer data and a higher coverage of exposure to vaccine, we replicated these findings using a marginal structural Cox model. We showed that administration of cholera vaccine after prostate cancer diagnosis is associated with a significant reduction in mortality (HR 0.46, 95% CI 0.31-0.69, p-value 0.0001) even after adjusting for all known confounders. However, the same effect (or even stronger) could be seen for several other traveling vaccines and malaria prophylaxis. Therefore, we conclude that this effect is most likely due to a healthy traveler bias and is an example of residual confounding.
Collapse
Affiliation(s)
- Axel Möller
- Department of Urology, Karolinska University Hospital Solna, Stockholm, Sweden; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
| | - Klaus Schwamborn
- VALNEVA SE, 6, rue Alain Bombard, 44800 Saint-Herblain, Nantes, France.
| | - Adrian Spillmann
- VALNEVA AUSTRIA GMBH, Campus Vienna Biocenter 3, 1030 Vienna, Austria.
| | | | - Robert Szulkin
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Sweden; SDS Life Science, Danderyd, Sweden.
| | - Olof Akre
- Department of Urology, Karolinska University Hospital Solna, Stockholm, Sweden; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
| | - Lars Egevad
- Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
| | - Mark Clements
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Sweden.
| | - Markus Aly
- Department of Urology, Karolinska University Hospital Solna, Stockholm, Sweden; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
| |
Collapse
|
5
|
Noske A, Wagner DC, Schwamborn K, Foersch S, Steiger K, Kiechle M, Karapetyan S, Oettler D, Hapfelmeier A, Roth W, Weichert W. 13P Comparison study of different programmed death-ligand 1 (PD-L1) assays, readers and scoring methods in triple-negative breast cancer (TNBC). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.03.027] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
6
|
Bischof O, Schwamborn K, Martin N, Werner A, Sustmann C, Grosschedl R, Dejean A. Retraction Notice to: The E3 SUMO Ligase PIASy Is a Regulator of Cellular Senescence and Apoptosis. Mol Cell 2020; 80:1140. [PMID: 33338405 DOI: 10.1016/j.molcel.2020.11.049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
7
|
Ortiz-Brüchle N, Muders M, Toma M, Esposito I, Hartmann A, Stöhr R, Reis H, Wild P, Köllermann J, Bremmer F, Leichsenring J, Stenzinger A, Merkelbach-Bruse S, Kirfel S, Perner S, Hartmann N, Roth W, Jung A, Kirchner T, Schwamborn K, Pfarr N, Dahl E, Knüchel R, Gaisa NT. [Status of the availability and use of next generation sequencing (NGS) in bladder cancer-a questionnaire within the uropathology working group]. Urologe A 2019; 59:318-325. [PMID: 31541269 DOI: 10.1007/s00120-019-01046-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
BACKGROUND Technical advancement and availability of high-throughput analysis has advanced molecular subtyping of most cancers. Thus, new possibilities for precision oncology have emerged. AIM Therefore, we aimed to collect data regarding availability and use of next generation sequencing (NGS) for urothelial cancer within the uropathology working group of the German Society of Pathology. METHODS We collected data by questionnaires and additionally asked for sequencing results of bladder cancers in the participating institutions. RESULTS A total of 13 university-affiliated institutes of pathology took part in the survey. All university institutes offer NGS-based molecular panel diagnostics and provide panels covering between 15 and 170 genes. Altogether, only 20 bladder cancers were sequenced in routine diagnostics and for 10 cancers potential targeted treatment options were available. DISCUSSION So far, despite availability of NGS diagnostics at university institutes of pathology, only few bladder cancer samples have been sequenced. Based on current data from the molecular subtyping of bladder cancers, we recommend a step-by-step protocol with basic immunohistochemistry analysis and subsequent subtype-dependent analyses, e.g., alterations of the fibroblast growth factor receptors (FGFR) or comprehensive gene panel analyses.
Collapse
Affiliation(s)
- N Ortiz-Brüchle
- Institut für Pathologie, Uniklinikum, RWTH Aachen, Pauelsstraße 30, 52074, Aachen, Deutschland
| | - M Muders
- Institut für Pathologie, Universitätsklinikum Bonn, Bonn, Deutschland
| | - M Toma
- Institut für Pathologie, Universitätsklinikum Bonn, Bonn, Deutschland
| | - I Esposito
- Institut für Pathologie, Universitätsklinikum Düsseldorf, Heinrich-Heine Universität, Düsseldorf, Deutschland
| | - A Hartmann
- Institut für Pathologie, Universitätsklinikum Erlangen, Erlangen, Deutschland
| | - R Stöhr
- Institut für Pathologie, Universitätsklinikum Erlangen, Erlangen, Deutschland
| | - H Reis
- Institut für Pathologie, Universitätsklinikum Essen, Essen, Deutschland
| | - P Wild
- Dr. Senckenbergisches Institut für Pathologie, Frankfurt, Deutschland
| | - J Köllermann
- Dr. Senckenbergisches Institut für Pathologie, Frankfurt, Deutschland
| | - F Bremmer
- Institut für Pathologie, Universitätsklinikum Göttingen, Göttingen, Deutschland
| | - J Leichsenring
- Molekularpathologisches Zentrum, Pathologisches Institut, Universitätsklinikum Heidelberg, Heidelberg, Deutschland
| | - A Stenzinger
- Molekularpathologisches Zentrum, Pathologisches Institut, Universitätsklinikum Heidelberg, Heidelberg, Deutschland
| | | | - S Kirfel
- Institut für Pathologie, Universitätsklinikum Lübeck, Lübeck, Deutschland
| | - S Perner
- Institut für Pathologie, Universitätsklinikum Lübeck, Lübeck, Deutschland
- Pathologie, Forschungszentrum Borstel, Leibniz Lungenzentrum, Borstel, Deutschland
| | - N Hartmann
- Institut für Pathologie, Universitätsklinikum Mainz, Mainz, Deutschland
| | - W Roth
- Institut für Pathologie, Universitätsklinikum Mainz, Mainz, Deutschland
| | - A Jung
- Pathologisches Institut, LMU München, München, Deutschland
| | - T Kirchner
- Pathologisches Institut, LMU München, München, Deutschland
| | - K Schwamborn
- Institut für Pathologie, TU München, München, Deutschland
| | - N Pfarr
- Institut für Pathologie, TU München, München, Deutschland
| | - E Dahl
- Institut für Pathologie, Uniklinikum, RWTH Aachen, Pauelsstraße 30, 52074, Aachen, Deutschland
| | - R Knüchel
- Institut für Pathologie, Uniklinikum, RWTH Aachen, Pauelsstraße 30, 52074, Aachen, Deutschland
| | - N T Gaisa
- Institut für Pathologie, Uniklinikum, RWTH Aachen, Pauelsstraße 30, 52074, Aachen, Deutschland.
| |
Collapse
|
8
|
Steiger K, Ballke S, Yen HY, Seelbach O, Alkhamas A, Boxberg M, Schwamborn K, Knolle PA, Weichert W, Mogler C. [Histopathological research laboratories in translational research : Conception and integration into the infrastructure of pathological institutes]. Pathologe 2019; 40:172-178. [PMID: 30027333 DOI: 10.1007/s00292-018-0458-2] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
A systematic review of histopathology from experimental animal systems is an essential part of up-to-date biomedical research. Pathologists at university hospitals are especially and increasingly challenged by these specialized and time-consuming duties. This article presents and analyzes a new laboratory structure of comparative experimental pathology-jointly lead by veterinary and human pathologists-which might solve this problem. The focus is on the establishment and full integration of this laboratory structure into a local, regional, and nationwide biomedical research cluster. A detailed comparison with an established structure of routine histopathology laboratories discusses merits and benefits as well as disadvantages.
Collapse
Affiliation(s)
- K Steiger
- Institut für allgemeine Pathologie und pathologische Anatomie, Technische Universität München, München, Deutschland. .,Comparative Experimental Pathology, Technische Universität München, München, Deutschland. .,Vergleichende Experimentelle Pathologie, Institut für Pathologie, Technische Universität München, Trogerstraße 18, 81675, München, Deutschland.
| | - S Ballke
- Institut für allgemeine Pathologie und pathologische Anatomie, Technische Universität München, München, Deutschland.,Comparative Experimental Pathology, Technische Universität München, München, Deutschland
| | - H-Y Yen
- Institut für allgemeine Pathologie und pathologische Anatomie, Technische Universität München, München, Deutschland.,Comparative Experimental Pathology, Technische Universität München, München, Deutschland.,Partnerstandort München, Deutsches Konsortium für Translationale Krebsforschung, München, Deutschland
| | - O Seelbach
- Institut für allgemeine Pathologie und pathologische Anatomie, Technische Universität München, München, Deutschland.,Comparative Experimental Pathology, Technische Universität München, München, Deutschland
| | - A Alkhamas
- Institut für allgemeine Pathologie und pathologische Anatomie, Technische Universität München, München, Deutschland.,Comparative Experimental Pathology, Technische Universität München, München, Deutschland.,Partnerstandort München, Deutsches Konsortium für Translationale Krebsforschung, München, Deutschland
| | - M Boxberg
- Institut für allgemeine Pathologie und pathologische Anatomie, Technische Universität München, München, Deutschland.,Comparative Experimental Pathology, Technische Universität München, München, Deutschland
| | - K Schwamborn
- Institut für allgemeine Pathologie und pathologische Anatomie, Technische Universität München, München, Deutschland.,Comparative Experimental Pathology, Technische Universität München, München, Deutschland
| | - P A Knolle
- Institut für Molekulare Immunologie, Klinikum rechts der Isar, Technische Universität München, München, Deutschland
| | - W Weichert
- Institut für allgemeine Pathologie und pathologische Anatomie, Technische Universität München, München, Deutschland.,Comparative Experimental Pathology, Technische Universität München, München, Deutschland.,Partnerstandort München, Deutsches Konsortium für Translationale Krebsforschung, München, Deutschland
| | - C Mogler
- Institut für allgemeine Pathologie und pathologische Anatomie, Technische Universität München, München, Deutschland.,Comparative Experimental Pathology, Technische Universität München, München, Deutschland
| |
Collapse
|
9
|
Nikolay A, Léon A, Schwamborn K, Genzel Y, Reichl U. Process intensification of EB66® cell cultivations leads to high-yield yellow fever and Zika virus production. Appl Microbiol Biotechnol 2018; 102:8725-8737. [PMID: 30091043 PMCID: PMC6153634 DOI: 10.1007/s00253-018-9275-z] [Citation(s) in RCA: 34] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2018] [Revised: 07/24/2018] [Accepted: 07/25/2018] [Indexed: 01/01/2023]
Abstract
A live-attenuated, human vaccine against mosquito-borne yellow fever virus has been available since the 1930s. The vaccine provides long-lasting immunity and consistent mass vaccination campaigns counter viral spread. However, traditional egg-based vaccine manufacturing requires about 12 months and vaccine supplies are chronically close to shortages. In particular, for urban outbreaks, vaccine demand can be covered rarely by global stockpiling. Thus, there is an urgent need for an improved vaccine production platform, ideally transferable to other flaviviruses including Zika virus. Here, we present a proof-of-concept study regarding cell culture-based yellow fever virus 17D (YFV) and wild-type Zika virus (ZIKV) production using duck embryo-derived EB66® cells. Based on comprehensive studies in shake flasks, 1-L bioreactor systems were operated with scalable hollow fiber-based tangential flow filtration (TFF) and alternating tangential flow filtration (ATF) perfusion systems for process intensification. EB66® cells grew in chemically defined medium to cell concentrations of 1.6 × 108 cells/mL. Infection studies with EB66®-adapted virus led to maximum YFV titers of 7.3 × 108 PFU/mL, which corresponds to about 10 million vaccine doses for the bioreactor harvest. For ZIKV, titers of 1.0 × 1010 PFU/mL were achieved. Processes were automated successfully using a capacitance probe to control perfusion rates based on on-line measured cell concentrations. The use of cryo-bags for direct inoculation of production bioreactors facilitates pre-culture preparation contributing to improved process robustness. In conclusion, this platform is a powerful option for next generation cell culture-based flavivirus vaccine manufacturing.
Collapse
Affiliation(s)
- Alexander Nikolay
- Max Planck Institute for Dynamics of Complex Technical Systems, Bioprocess Engineering, Magdeburg, Sandtorstr. 1, 39106, Magdeburg, Germany
| | - Arnaud Léon
- Valneva SE, 6 rue Alain Bombard, 44800, Saint-Herblain, France
| | | | - Yvonne Genzel
- Max Planck Institute for Dynamics of Complex Technical Systems, Bioprocess Engineering, Magdeburg, Sandtorstr. 1, 39106, Magdeburg, Germany.
| | - Udo Reichl
- Max Planck Institute for Dynamics of Complex Technical Systems, Bioprocess Engineering, Magdeburg, Sandtorstr. 1, 39106, Magdeburg, Germany
- Otto von Guericke University Magdeburg, Universitätsplatz 2, 39106, Magdeburg, Germany
| |
Collapse
|
10
|
Schwamborn K. Back to the future – Is the drug repositioning concept applicable to vaccines? Vaccine 2018; 36:2743-2744. [DOI: 10.1016/j.vaccine.2018.04.020] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2018] [Revised: 04/06/2018] [Accepted: 04/09/2018] [Indexed: 11/28/2022]
|
11
|
Abstract
Mass spectrometry imaging (MSI) has become a valuable tool in cancer research. Even more, due to its capability to directly link molecular changes with histology, it holds the prospect to revolutionize tissue-based diagnostics. In order to learn to walk before running, however, information obtained through classical histology should not be neglected but rather used to its full capacity and integrated with mass spectrometry data to lead to a superior molecular histology synthesis. In order to achieve this, pathomorphological analyses have to be integrated into MSI analyses right from the beginning to avoid errors and pitfalls of MSI application possibly leading to incorrect or imprecise study outcomes. Such errors can be caused by different sample or tissue inherent factors or through factors in sample preparation. Future studies should, therefore, aim for a comprehensive incorporation of histology and pathology characteristics to ensure the generation of high-quality data in MSI to exploit its full capacity in tissue-based basic and translational research.
Collapse
|
12
|
Léon A, David AL, Madeline B, Guianvarc'h L, Dureau E, Champion-Arnaud P, Hebben M, Huss T, Chatrenet B, Schwamborn K. The EB66® cell line as a valuable cell substrate for MVA-based vaccines production. Vaccine 2016; 34:5878-5885. [PMID: 27997338 DOI: 10.1016/j.vaccine.2016.10.043] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2016] [Revised: 10/15/2016] [Accepted: 10/17/2016] [Indexed: 11/17/2022]
Abstract
The selection of a cell substrate is a critical step for the development and manufacturing of a viral vaccine candidate. Several parameters such as cell susceptibility and permissiveness to the viral pathogens but also performance in terms of viral antigens quality and production yields are important considerations when identifying the ideal match between a viral vaccine and cell substrate. The modified vaccinia virus Ankara (MVA) is a replication-deficient viral vector that holds great promise as a vaccine platform, however only limited cell substrates have been tested or are available for industrialization. Here we evaluate the duck embryo-derived EB66® cell line as potential cell substrate for MVA production. To this end, we used two recombinant MVA constructs and demonstrated that EB66® cells are propagating the tested MVA viruses very efficiently, while preserving viral attenuation and transgene expression for up to 20 serial passages. Furthermore we developed upstream and downstream processes that enable industrialization of the virus production. In conclusion, we showed that EB66® cells can be used as potent cell substrate for MVA-based vaccines and represent therefore an attractive alternative for vaccine production.
Collapse
Affiliation(s)
- Arnaud Léon
- Valneva SE, 6 rue Alain Bombard, 44800 Saint-Herblain, France.
| | | | - Brice Madeline
- Valneva SE, 6 rue Alain Bombard, 44800 Saint-Herblain, France
| | | | - Elodie Dureau
- Valneva SE, 6 rue Alain Bombard, 44800 Saint-Herblain, France
| | | | - Matthias Hebben
- Valneva SE, 6 rue Alain Bombard, 44800 Saint-Herblain, France
| | - Thierry Huss
- Transgene SA, 400 boulevard Gonthier d'Andernach - Parc d'Innovation - CS80166, 67405 Illkirch Graffenstaden cedex, France
| | | | | |
Collapse
|
13
|
Konrad S, Schwamborn K, Hellmann D, Schmalfeldt B, Kiechle M, Meindl A, Ramser J. Identification and characterization of a specific neuronal calcium sensor protein as novel prognostic and predictive biomarker for ovarian cancer therapy. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1592966] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
14
|
Tanios F, Pelisek J, Lutz B, Reutersberg B, Matevossian E, Schwamborn K, Hösel V, Eckstein HH, Reeps C. CXCR4: A Potential Marker for Inflammatory Activity in Abdominal Aortic Aneurysm Wall. Eur J Vasc Endovasc Surg 2015; 50:745-53. [PMID: 26346005 DOI: 10.1016/j.ejvs.2015.07.040] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2015] [Accepted: 07/30/2015] [Indexed: 12/27/2022]
Abstract
OBJECTIVES The aim of the study was to evaluate the potential role of chemokine receptor CXCR4 and its ligand CXCL12 in the pathogenesis of abdominal aortic aneurysm (AAA). METHODS AAA tissue specimens were obtained from the anterior or lateral aneurysm sac of patients (n = 32, 26 males, 6 females; 66.8 ± 11.2 years, diameter 64.4 ± 17.0 mm), who underwent elective open surgical repair. Twelve non-aneurysmal aortic specimens from transplant donors served as controls. Expression analysis of CXCR4 and CXCL12 at mRNA and protein level was determined by quantitative reverse transcription-polymerase chain reaction (RT-PCR) and western blot. Immunohistochemical staining of corresponding histological sections for CD3 (T-cells), CD20 (B-cells), and CD68 (macrophages) was performed to determine the cellular localization of CXCR4 and CXCL12. Data were analyzed with SPSS 20.0 using Mann-Whitney U test and Spearman's rank correlation coefficient. RESULTS Gene expression of CXCR4 and CXCL12 was 9.6 and 4.6 fold higher in AAA than in non-aneurysmal aorta (p = .0004 and p < .0001, respectively). Likewise, the protein level of CXCR4 was increased 3.2 fold in AAA wall compared with non-aneurysmal aortic tissue (p < .0001), although CXCL12 could not be detected. Immunohistochemical analysis revealed that CXCR4 was expressed in B and T lymphocytes and macrophages, and CXCL12 was observed only in plasma cells. CONCLUSIONS This study confirmed the over expression of CXCR4 in human AAA tissue. CXCR4 was detected both at the mRNA and the protein level and by immunohistochemistry, especially in inflammatory cells. In contrast, CXCL12 expression was observed only at the mRNA level, with the exception of plasma cells. The exact role of CXCR4/CXCL12 in AAA has to be further elucidated.
Collapse
Affiliation(s)
- F Tanios
- Department of Vascular and Endovascular Surgery, Klinikum rechts der Isar, Munich, Germany
| | - J Pelisek
- Department of Vascular and Endovascular Surgery, Klinikum rechts der Isar, Munich, Germany.
| | - B Lutz
- Department of Vascular and Endovascular Surgery, Klinikum rechts der Isar, Munich, Germany
| | - B Reutersberg
- Department of Vascular and Endovascular Surgery, Klinikum rechts der Isar, Munich, Germany
| | - E Matevossian
- Department of Surgery, Munich Transplant Centre, Klinikum rechts der Isar, Munich, Germany
| | - K Schwamborn
- Institute of Pathology, Klinikum rechts der Isar, Munich, Germany
| | - V Hösel
- Department of Mathematical Modeling of Biological Systems, Technische Universität München, Munich, Germany
| | - H-H Eckstein
- Department of Vascular and Endovascular Surgery, Klinikum rechts der Isar, Munich, Germany
| | - C Reeps
- Department of Vascular and Endovascular Surgery, Klinikum rechts der Isar, Munich, Germany
| |
Collapse
|
15
|
Boshuizen RS, Marsden C, Turkstra J, Rossant CJ, Slootstra J, Copley C, Schwamborn K. A combination of in vitro techniques for efficient discovery of functional monoclonal antibodies against human CXC chemokine receptor-2 (CXCR2). MAbs 2015; 6:1415-24. [PMID: 25484047 DOI: 10.4161/mabs.36237] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
BACKGROUND Development of functional monoclonal antibodies against intractable GPCR targets. RESULTS Identification of structured peptides mimicking the ligand binding site, their use in panning to enrich for a population of binders, and the subsequent challenge of this population with receptor overexpressing cells leads to functional monoclonal antibodies. CONCLUSION The combination of techniques provides a successful strategic approach for the development of functional monoclonal antibodies against CXCR2 in a relatively small campaign. SIGNIFICANCE The presented combination of techniques might be applicable for other, notoriously difficult, GPCR targets. SUMMARY The CXC chemokine receptor-2 (CXCR2) is a member of the large 'family A' of G-protein-coupled-receptors and is overexpressed in various types of cancer cells. CXCR2 is activated by binding of a number of ligands, including interleukin 8 (IL-8) and growth-related protein α (Gro-α). Monoclonal antibodies capable of blocking the ligand-receptor interaction are therefore of therapeutic interest; however, the development of biological active antibodies against highly structured GPCR proteins is challenging. Here we present a combination of techniques that improve the discovery of functional monoclonal antibodies against the native CXCR2 receptor. The IL-8 binding site of CXCR2 was identified by screening peptide libraries with the IL-8 ligand, and then reconstructed as soluble synthetic peptides. These peptides were used as antigens to probe an antibody fragment phage display library to obtain subpopulations binding to the IL-8 binding site of CXCR2. Further enrichment of the phage population was achieved by an additional selection round with CXCR2 overexpressing cells as a different antigen source. The scFvs from the CXCR2 specific phage clones were sequenced and converted into monoclonal antibodies. The obtained antibodies bound specifically to CXCR2 expressing cells and inhibited the IL-8 and Gro-α induced ß-arrestin recruitment with IC50 values of 0.3 and 0.2 nM, respectively, and were significantly more potent than the murine monoclonal antibodies (18 and 19 nM, respectively) obtained by the classical hybridoma technique, elicited with the same peptide antigen. According to epitope mapping studies, the antibody efficacy is largely defined by N-terminal epitopes comprising the IL-8 and Gro-α binding sites. The presented strategic combination of in vitro techniques, including the use of different antigen sources, is a powerful alternative for the development of functional monoclonal antibodies by the classical hybridoma technique, and might be applicable to other GPCR targets.
Collapse
Key Words
- ABTS, 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid)
- BSA, bovine serum albumin
- CLIPS™, Chemical LInkage of Peptides onto Scaffolds
- CXCR2
- ECL, extracellular loop
- EDTA, ethylenediaminetetraacetic acid
- ELISA, enzyme-linked immunoabsorbent assay
- Fmoc, fluorenylmethyloxycarbonyl
- GPCR
- GPCR, G-protein coupled receptor
- Gro-α, growth-related protein α
- IL-8, interleukin 8
- IPTG, isopropyl β-D-1-thiogalactopyranoside
- MFI, mean fluorescence intensity
- PBS, phosphate buffer saline
- PCR, polymerase chain reaction
- PEG, polyethyleneglycol
- TES, 2-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]amino]ethanesulfonic acid
- TRIS, tris(hydroxymethyl)aminomethane
- ligand inhibition
- monoclonal antibody
- phage display library
- scFv, single-chain variable fragment
Collapse
|
16
|
Aubrit F, Perugi F, Léon A, Guéhenneux F, Champion-Arnaud P, Lahmar M, Schwamborn K. Cell substrates for the production of viral vaccines. Vaccine 2015; 33:5905-12. [PMID: 26187258 DOI: 10.1016/j.vaccine.2015.06.110] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2015] [Revised: 06/12/2015] [Accepted: 06/26/2015] [Indexed: 11/20/2022]
Abstract
Vaccines have been used for centuries to protect people and animals against infectious diseases. For vaccine production, it has become evident that cell culture technology can be considered as a key milestone and has been the result of decades of progress. The development and implementation of cell substrates have permitted massive and safe production of viral vaccines. The demand in new vaccines against emerging viral diseases, the increasing vaccine production volumes, and the stringent safety rules for manufacturing have made cell substrates mandatory viral vaccine producer factories. In this review, we focus on cell substrates for the production of vaccines against human viral diseases. Depending on the nature of the vaccine, choice of the cell substrate is critical. Each manufacturer intending to develop a new vaccine candidate should assess several cell substrates during the early development phase in order to select the most convenient for the application. First, as vaccine safety is quite naturally a central concern of Regulatory Agencies, the cell substrate has to answer the regulatory rules stringency. In addition, the cell substrate has to be competitive in terms of viral-specific production yields and manufacturing costs. No cell substrate, even the so-called "designer" cell lines, is able to fulfil all the requested criteria for all viral vaccines. Therefore, the availability of a variety of cell substrates for vaccine production is essential because it improves the chance to successfully respond to the current and future needs of vaccines linked to new emerging or re-emerging infectious diseases (e.g. pandemic flu, Ebola, and Chikungunya outbreaks).
Collapse
Affiliation(s)
- Françoise Aubrit
- Vaccines Research & Discovery Department, Valneva SE, 6 rue Alain Bombard, 44800 Saint-Herblain, France.
| | - Fabien Perugi
- Vaccines Research & Discovery Department, Valneva SE, 6 rue Alain Bombard, 44800 Saint-Herblain, France.
| | - Arnaud Léon
- Vaccines Research & Discovery Department, Valneva SE, 6 rue Alain Bombard, 44800 Saint-Herblain, France.
| | - Fabienne Guéhenneux
- Vaccines Research & Discovery Department, Valneva SE, 6 rue Alain Bombard, 44800 Saint-Herblain, France.
| | - Patrick Champion-Arnaud
- Vaccines Research & Discovery Department, Valneva SE, 6 rue Alain Bombard, 44800 Saint-Herblain, France.
| | - Mehdi Lahmar
- Vaccines Research & Discovery Department, Valneva SE, 6 rue Alain Bombard, 44800 Saint-Herblain, France.
| | - Klaus Schwamborn
- Vaccines Research & Discovery Department, Valneva SE, 6 rue Alain Bombard, 44800 Saint-Herblain, France.
| |
Collapse
|
17
|
Kriegsmann M, Seeley EH, Schwarting A, Kriegsmann J, Otto M, Thabe H, Dierkes B, Biehl C, Sack U, Wellmann A, Kahaly GJ, Schwamborn K, Caprioli RM. MALDI MS imaging as a powerful tool for investigating synovial tissue. Scand J Rheumatol 2012; 41:305-9. [PMID: 22639849 DOI: 10.3109/03009742.2011.647925] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
OBJECTIVE To identify and image protein biomarker candidates in the synovial tissue of patients with rheumatoid arthritis (RA) and patients with osteoarthritis (OA). METHODS A novel matrix-assisted laser desorption/ionization (MALDI) imaging mass spectrometry (IMS) technique was applied to the analysis of synovial tissue. Patients were classified according to the American College of Rheumatology (ACR) criteria for RA. Frozen sections were stained to obtain morphological data. Serial sections were desiccated, and spotted with matrix for MALDI analysis. Ions generated by laser irradiation of the tissue were separated in time, based on their m/z ratio, and were subsequently detected. IMS was used in a 'profiling' mode to detect discrete spots for rapid evaluation of proteomic patterns in various tissue compartments. Photomicrographs of the stained tissue images were reviewed by a pathologist. Areas of interest (10 discrete areas/compartment) were marked digitally and the histology-annotated images were merged to form a photomicrograph of the section taken before the MALDI measurement. Pixel coordinates of these areas were transferred to a robotic spotter, the matrix was spotted, and the coordinates of the spots were transferred to a mass spectrometer for spectral acquisition. The data generated were then subjected to biocomputation analysis to reveal the biomarker candidates. RESULTS Several peaks (m/z) consistent in mass with calgranulins, defensins, and thymosins were detected and their distribution in various synovial compartments (synovial lining and sublining layer) was demonstrated. CONCLUSION MALDI IMS is a powerful tool for the rapid detection of numerous proteins (in situ proteomics) and was applied here for the analysis of the distribution of proteins in synovial tissue sections.
Collapse
Affiliation(s)
- M Kriegsmann
- Department of Clinical Immunology, Medical Faculty, University of Leipzig, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Martin N, Schwamborn K, Schreiber V, Werner A, Guillier C, Zhang XD, Bischof O, Seeler JS, Dejean A. PARP-1 transcriptional activity is regulated by sumoylation upon heat shock. EMBO J 2009; 28:3534-48. [PMID: 19779455 DOI: 10.1038/emboj.2009.279] [Citation(s) in RCA: 95] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2009] [Accepted: 08/27/2009] [Indexed: 11/09/2022] Open
Abstract
Heat shock and other environmental stresses rapidly induce transcriptional responses subject to regulation by a variety of post-translational modifications. Among these, poly(ADP-ribosyl)ation and sumoylation have received growing attention. Here we show that the SUMO E3 ligase PIASy interacts with the poly(ADP-ribose) polymerase PARP-1, and that PIASy mediates heat shock-induced poly-sumoylation of PARP-1. Furthermore, PIASy, and hence sumoylation, appears indispensable for full activation of the inducible HSP70.1 gene. Chromatin immunoprecipitation experiments show that PIASy, SUMO and the SUMO-conjugating enzyme Ubc9 are rapidly recruited to the HSP70.1 promoter upon heat shock, and that they are subsequently released with kinetics similar to PARP-1. Finally, we provide evidence that the SUMO-targeted ubiquitin ligase RNF4 mediates heat-shock-inducible ubiquitination of PARP-1, regulates the stability of PARP-1, and, like PIASy, is a positive regulator of HSP70.1 gene activity. These results, thus, point to a novel mechanism for regulating PARP-1 transcription function, and suggest crosstalk between sumoylation and RNF4-mediated ubiquitination in regulating gene expression in response to heat shock.
Collapse
Affiliation(s)
- Nadine Martin
- Department of Cell Biology and Infection, Nuclear Organisation and Oncogenesis Unit, INSERM U579, Institut Pasteur, Paris, France
| | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Schwamborn K, Wiebe B, Reinhard H, Ehlen M. Ikterus gravis mit Bilirubinwerten von 43,15mg/dl bei gemeinsamem Auftreten von M. Meulengracht und Sphärozytose. Z Geburtshilfe Neonatol 2009. [DOI: 10.1055/s-0029-1223061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
20
|
Braunschweig T, Krieg RC, Bar-Or R, Smeets D, Schwamborn K, Fogt F, Nagel H, Hemmerlein B, Wellmann A. Protein profiling of non-malignant and malignant ascites by SELDI-TOF MS: proof of principle. Int J Mol Med 2009; 23:3-8. [PMID: 19082501] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023] Open
Abstract
Ascites is a common clinical symptom in liver cirrhosis, inflammatory disorders of the abdomen and a major late manifestation of metastatic malignancies. Standard cytopathological techniques and immunocytochemistry have specificities and sensitivities of approximately 95 and 60%, respectively for the presence of tumor cells. Development of faster and more accurate screening methods would be of great clinical utility. In this work we examined differential analysis of the unbound proteins in the supernatant of ascites fluid by Protein-Chip SELDI mass spectrometry. There were 21 tumor cell-positive and 34 tumor cell-negative samples. We used principal component analysis coupled with linear regression applied to the mass spectra of the samples to distinguish between the sample groups. Two sample sets for statistical analysis were created after randomization, a training set with 37 samples and a validation set with 18 samples resulting in a specificity of 93% and a sensitivity of 83% on the training set. The validation set yielded a specificity and sensitivity of 75%. This study suggests that SELDI-TOF mass spectrometry appears to have great potential as a surrogate diagnostic tool to evaluate effusion specimens.
Collapse
Affiliation(s)
- T Braunschweig
- Institute of Pathology, RWTH Aachen University, Aachen, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Wölfler MM, Schwamborn K, Otten D, Hornung D, Knüchel-Clarke R, Rath W. Proteomisches Profiling von Serum und Aszites im Vergleich bei Patientinnen mit und ohne Endometriose. Geburtshilfe Frauenheilkd 2008. [DOI: 10.1055/s-0028-1089227] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
22
|
Wölfler MM, Siehs C, Schwamborn K, Otten D, Knüchel-Clarke R, Rath W. Nachweis von Aromatase-Expression im eutopen Endometrium mittels reverse-phase Protein Arraying bei Patientinnen mit Endometriose. Geburtshilfe Frauenheilkd 2008. [DOI: 10.1055/s-0028-1089080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
23
|
Schwamborn K, Knipscheer P, van Dijk E, van Dijk WJ, Sixma TK, Meloen RH, Langedijk JPM. SUMO assay with peptide arrays on solid support: insights into SUMO target sites. J Biochem 2008; 144:39-49. [PMID: 18344540 DOI: 10.1093/jb/mvn039] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
The modification of proteins by SUMO (small ubiquitin-like modifier) regulates various cellular processes. Sumoylation often occurs on a specific lysine residue within the consensus motif psiKxE/D. However, little is known about the specificity and selectivity of SUMO target sites. We describe here a SUMO assay with peptide array on solid support for the simultaneous characterization of hundreds of different SUMO target sites. This approach was used to characterize known SUMO substrates. The position of the motif within the peptide and the amino acids flanking the acceptor site affected the efficiency of SUMO modification. Interestingly, a sequence of only four amino acids, corresponding to the SUMO consensus motif without flanking amino acids, was a bona fide target site. Analysis of a peptide library for all variants of the psiKxE/D consensus motif revealed that the first and third positions in the tetrapeptide preferably contain aromatic amino acid residues. Furthermore, by adding the SUMO E3 ligase PIAS1 to the reaction mixture, we show specific enhancement of the modification of a PIAS1-dependent SUMO substrate in this system. Overall, our results demonstrate that the sumoylation assay with peptide array on solid support can be used for the high-throughput characterization of SUMO target sites, and provide new insights into the composition, selectivity and specificity of SUMO target sites.
Collapse
Affiliation(s)
- Klaus Schwamborn
- Pepscan Therapeutics BV, Zuidersluisweg 2, 8243 RC Lelystad, the Netherlands.
| | | | | | | | | | | | | |
Collapse
|
24
|
Pecks U, Bartz C, Schwamborn K, Yagmur E, Stepan H, Schmidt M, Schlembach D, Rath W. MALDI TOF Massenspektrometrie zur Diagnostik der Präeklampsie und der Vergleich mit den Serummarkern PlGF, sFlt1 und Endoglin. Geburtshilfe Frauenheilkd 2008. [DOI: 10.1055/s-2008-1075777] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
25
|
Krieg RC, Herr A, Raupach K, Ren Q, Schwamborn K, Knuechel R. Analyzing effects of photodynamic therapy with 5-aminolevulinic acid (ALA) induced protoporphyrin IX (PPIX) in urothelial cells using reverse phase protein arrays. Photochem Photobiol Sci 2007; 6:1296-305. [PMID: 18046485 DOI: 10.1039/b704464j] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Photodynamic therapy (PDT) using 5-aminolevulinic acid (ALA)-induced protoporphyrin IX (PPIX) is clinically established approach for a number of defined applications. However, in order to optimize the therapeutic benefits of PDT, the specific mode of cell destruction should be better defined. Apoptosis is favored over necrosis for clinical practice as the latter causes more side-effects. In the present study, we analyse PDT-induced cell death and its correlation to various PDT parameters (different doses applied, time after PDT treatment) in vitro using reverse phase protein arrays. Human urothelial cell lines with varying degrees of differentiation (UROtsa, RT4, RT112, J82) were subjected to in vitro-PDT using increasing doses of irradiation. In addition, positive controls for apoptosis, necrosis and un-/specific cellular damage were included. Cells were harvested over a specified time course, lysed and arrayed onto nitrocellulose-covered glass slides. The arrays were analyzed for expression of apoptosis-related proteins by immunohistochemistry. Analysis of caspase-3 and -9 expression, the activation of HIF-1alpha, Bcl2, Cox2 and the phosphorylation of AKT reveals signal activation due to a PDT-stimulus in correlation with the positive controls. Data were analyzed by unsupervised hierarchical clustering and depicted as a heat map revealing cell-specific patterns of pathway stimulation. Higher differentiated phenotypes showed a more distinct signal response in general and a higher apoptotic response in detail. Lower differentiated cell lines lost pathway regulation capabilities according to their state of dedifferentiation. Reverse phase protein arrays are a promising technique for signal pathway profiling: they exceed the range of traditional western blots by sensitivity, high-throughput capability, minimal sample consumption and easy quantification of results obtained.
Collapse
Affiliation(s)
- R C Krieg
- Institute of Pathology, Pauwelsstr. 30, RWTH Aachen University, Aachen, D-52074, Germany.
| | | | | | | | | | | |
Collapse
|
26
|
Mühlfeld AS, Ketteler M, Schwamborn K, Eitner F, Schneider B, Gladziwa U, Knüchel R, Floege J. Sticky platelet syndrome: an underrecognized cause of graft dysfunction and thromboembolic complications in renal transplant recipients. Am J Transplant 2007; 7:1865-8. [PMID: 17532753 DOI: 10.1111/j.1600-6143.2007.01835.x] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Sticky platelet syndrome (SPS) leads to hyperaggregabilty of platelets in response to physiologic stimuli. In this report we describe three patients with clinical symptoms of SPS after renal transplantation. The first patient developed an infarction of her transplant kidney with additional, subsequent renal microinfarctions. The second patient suffered multiple strokes and deep vein thrombosis with episodes of pulmonary embolism and ischemic bowel disease due to colonic microinfarctions. The third patient experienced a long episode of unexplained respiratory and graft dysfunction immediately after transplantation until therapy for SPS was initiated, at which point symptoms resolved quickly. Kidney transplant recipients with SPS may be at increased risk of developing thrombosis, given that most immunosuppressive drugs are known to induce either endothelial cell damage or augment platelet aggregation. All patients awaiting renal transplantation should be screened for a history of thrombosis and, if appropriate, tested for SPS. Affected patients should receive dose-adjusted acetylsalicylic acid.
Collapse
Affiliation(s)
- A S Mühlfeld
- Division of Nephrology and Immunology, University of Aachen, Aachen, Germany
| | | | | | | | | | | | | | | |
Collapse
|
27
|
Bischof O, Schwamborn K, Martin N, Werner A, Sustmann C, Grosschedl R, Dejean A. RETRACTED: The E3 SUMO Ligase PIASy Is a Regulator of Cellular Senescence and Apoptosis. Mol Cell 2006; 22:783-794. [PMID: 16793547 DOI: 10.1016/j.molcel.2006.05.016] [Citation(s) in RCA: 127] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2005] [Revised: 03/30/2006] [Accepted: 05/11/2006] [Indexed: 10/24/2022]
Abstract
Cellular senescence and apoptosis have evolved to restrain unwarranted proliferation of potentially tumorigenic cells. Here we show that overexpression of the E3 SUMO ligase PIASy in normal human fibroblasts recruits the p53 and Rb tumor suppressor pathways to provoke a senescence arrest. By contrast, in Rb-deficient fibroblasts, expression of PIASy leads to p53-dependent apoptosis. Induction of senescence requires PIASy E3 activity and is specific for this member of the PIAS ligase family. PIASy stimulates sumoylation and transcriptional activity of p53 and increases Rb-dependent corepression through recruitment to E2F-responsive promoters. Viral oncoprotein E6 suppresses both PIASy-induced senescence and sumoylation of PIASy substrates. Finally, we show that fibroblasts lacking PIASy exhibit a highly reduced propensity to undergo senescence in response to a prosenescence stimulus. Altogether, these data provide the first evidence for a direct role of an E3 SUMO ligase, and by implication of the SUMO pathway, in cellular senescence and apoptosis.
Collapse
Affiliation(s)
- Oliver Bischof
- Nuclear Organisation and Oncogenesis Unit, INSERM U579, Institut Pasteur, 75724 Paris Cedex 15, France
| | - Klaus Schwamborn
- Nuclear Organisation and Oncogenesis Unit, INSERM U579, Institut Pasteur, 75724 Paris Cedex 15, France
| | - Nadine Martin
- Nuclear Organisation and Oncogenesis Unit, INSERM U579, Institut Pasteur, 75724 Paris Cedex 15, France
| | - Andreas Werner
- Nuclear Organisation and Oncogenesis Unit, INSERM U579, Institut Pasteur, 75724 Paris Cedex 15, France
| | - Claudio Sustmann
- Max-Planck-Institute of Immunobiology, D-79108 Freiburg, Germany
| | | | - Anne Dejean
- Nuclear Organisation and Oncogenesis Unit, INSERM U579, Institut Pasteur, 75724 Paris Cedex 15, France.
| |
Collapse
|
28
|
Kravchenko VV, Mathison JC, Schwamborn K, Mercurio F, Ulevitch RJ. IKKi/IKKepsilon plays a key role in integrating signals induced by pro-inflammatory stimuli. J Biol Chem 2003; 278:26612-9. [PMID: 12736252 DOI: 10.1074/jbc.m303001200] [Citation(s) in RCA: 104] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
We report that the product of the inducible gene encoding the kinase known as IKKi/IKKepsilon (IKKi) is required for expression of a group of genes up-regulated by pro-inflammatory stimuli such as bacterial endotoxin (lipopolysaccharide (LPS)). Here, using murine embryonic fibroblasts obtained from mice bearing deletions in IKK2, p65, and IKKi genes, we provide evidence to support a link between signaling through the NF-kappaB and CCAAA/enhancer-binding protein (C/EBP) pathways. This link includes an NF-kappaB-dependent regulation of C/EBPbeta and C/EBPdelta gene transcription and IKKi-mediated activation of C/EBP. Disruption of the NF-kappaB pathway results in the blockade of the inducible up-regulation of C/EBPbeta, C/EBPdelta, and IKKi genes. Cells lacking IKKi are normal in activation of the canonical NF-kappaB pathway but fail to induce C/EBPdelta activity and transcription of C/EBP and C/EBP-NF-kappaB target genes in response to LPS. In addition we show that, in response to LPS or tumor necrosis factor alpha, both beta and delta subunits of C/EBP interact with IKKi promoter, suggesting a feedback mechanism in the regulation of IKKi-dependent cellular processes. These data are among the first to provide insights into the biological function of IKKi.
Collapse
|
29
|
Weil R, Schwamborn K, Alcover A, Bessia C, Di Bartolo V, Israël A. Induction of the NF-kappaB cascade by recruitment of the scaffold molecule NEMO to the T cell receptor. Immunity 2003; 18:13-26. [PMID: 12530972 DOI: 10.1016/s1074-7613(02)00506-x] [Citation(s) in RCA: 59] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
The mechanism by which TCR signaling activates NF-kappaB is poorly understood. We demonstrate here that the IKK kinase complex is recruited to the immunological synapse and can be coprecipitated with the TCR after T cell activation. Using ZAP-70-deficient T cells expressing a hybrid molecule between the SH2 domain of ZAP-70 and NEMO/IKKgamma, we showed that targeting NEMO to the immunological synapse, and more specifically its 120 N-terminal amino acids, was sufficient to selectively restore NF-kappaB activation in response to TCR ligation. Finally, we demonstrated that targeting of NEMO to the membrane of T cells was sufficient to induce constitutive NF-kappaB activation. This study shows that the localization of NEMO to the immunological synapse is important for TCR-induced NF-kappaB activation and offers a powerful system to dissect the NF-kappaB cascade in T cells.
Collapse
Affiliation(s)
- Robert Weil
- Unité de Biologie Moléculaire de l'Expression Génique, FRE 2364 Centre National de la Recherche Scientifique (CNRS), 75724 Paris Cedex 15, France.
| | | | | | | | | | | |
Collapse
|
30
|
Abstract
Altered gene expression contributes to the aetiology of inflammatory disease by modulation of the concentration of disease-related proteins. The expression of inflammatory genes is controlled through the concerted actions of specific transcription factors. Signal transduction networks positively or negatively regulate the activity of these transcription factors. Key components of these networks are protein kinases, which phosphorylate substrates on tyrosine, threonine or serine residues. During the disease process, pro-inflammatory signalling at the cell surface leads to a cascade of kinase activation, which ultimately culminates in modulation of the activity of transcription factors. Thus, pharmacological inhibition of protein kinases is a potential therapeutic strategy to treat inflammation. There are approximately 500 protein kinases in the human genome. Targeted small molecule inhibitors of these kinases should allow for tissue- and disease-specific therapies of unprecedented selectivity. Heralding this new era in molecular medicine is imatinib (Gleevec, Norvartis) a recently marketed tyrosine kinase inhibitor. This review focuses on kinase inhibitors that are currently in development for inflammatory diseases and the transcription factors that are involved.
Collapse
Affiliation(s)
- Gordon Alton
- Biochemistry Department, Pfizer Global Research and Development, La Jolla Laboratories, 4215 Sorrento Valley Boulevard, San Diego, CA 92121, USA.
| | | | | | | |
Collapse
|
31
|
Schwamborn K, Weil R, Courtois G, Whiteside ST, Israël A. Phorbol esters and cytokines regulate the expression of the NEMO-related protein, a molecule involved in a NF-kappa B-independent pathway. J Biol Chem 2000; 275:22780-9. [PMID: 10807909 DOI: 10.1074/jbc.m001500200] [Citation(s) in RCA: 84] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
The NF-kappaB signaling pathway plays a crucial role in the immune, inflammatory, and apoptotic responses. Recently, we identified the NF-kappaB Essential Modulator (NEMO) as an essential component of this pathway. NEMO is a structural and regulatory subunit of the high molecular kinase complex (IKK) responsible for the phosphorylation of NF-kappaB inhibitors. Data base searching led to the isolation of a cDNA encoding a protein we called NRP (NEMO-related protein), which shows a strong homology to NEMO. Here we show that NRP is present in a novel high molecular weight complex, that contains none of the known members of the IKK complex. Consistently, we could not observe any effect of NRP on NF-kappaB signaling. Nonetheless, we could demonstrate that treatment with phorbol esters induces NRP phosphorylation and decreases its half-life. This phosphorylation event could only be inhibited by K-252a and stauroporin. We also show that de novo expression of NRP can be induced by interferon and tumor necrosis factor alpha and that these two stimuli have a synergistic effect on NRP expression. In addition, we observed that endogenous NRP is associated with the Golgi apparatus. Analogous to NEMO, we find that NRP is associated in a complex with two kinases, suggesting that NRP could play a similar role in another signaling pathway.
Collapse
Affiliation(s)
- K Schwamborn
- Unité de Biologie Moléculaire de l'Expression Génique, URA 1773 Centre National de la Recherche Scientifique, Institut Pasteur, 25 Rue du Dr. Roux, 75724 Paris Cedex 15, France
| | | | | | | | | |
Collapse
|
32
|
Jäkel S, Albig W, Kutay U, Bischoff FR, Schwamborn K, Doenecke D, Görlich D. The importin beta/importin 7 heterodimer is a functional nuclear import receptor for histone H1. EMBO J 1999; 18:2411-23. [PMID: 10228156 PMCID: PMC1171324 DOI: 10.1093/emboj/18.9.2411] [Citation(s) in RCA: 197] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Import of proteins into the nucleus proceeds through nuclear pore complexes and is largely mediated by nuclear transport receptors of the importin beta family that use direct RanGTP-binding to regulate the interaction with their cargoes. We investigated nuclear import of the linker histone H1 and found that two receptors, importin beta (Impbeta) and importin 7 (Imp7, RanBP7), play a critical role in this process. Individually, the two import receptors bind H1 weakly, but binding is strong for the Impbeta/Imp7 heterodimer. Consistent with this, import of H1 into nuclei of permeabilized mammalian cells requires exogenous Impbeta together with Imp7. Import by the Imp7/Impbeta heterodimer is strictly Ran dependent, the Ran-requiring step most likely being the disassembly of the cargo-receptor complex following translocation into the nucleus. Disassembly is brought about by direct binding of RanGTP to Impbeta and Imp7, whereby the two Ran-binding sites act synergistically. However, whereas an Impbeta/RanGTP interaction appears essential for H1 import, Ran-binding to Imp7 is dispensable. Thus, Imp7 can function in two modes. Its Ran-binding site is essential when operating as an autonomous import receptor, i.e. independently of Impbeta. Within the Impbeta/Imp7 heterodimer, however, Imp7 plays a more passive role than Impbeta and resembles an import adapter.
Collapse
Affiliation(s)
- S Jäkel
- Zentrum für Molekulare Biologie der Universität Heidelberg, Im Neuenheimer Feld 282, D-69120 Heidelberg, Germany
| | | | | | | | | | | | | |
Collapse
|
33
|
Abstract
We have investigated the nuclear transport of the replacement histone H1(0) and have searched for its nuclear localization sequence (NLS). The lysine-rich H1(0) histone differs from the other H1 histones with respect to its mode of expression and to the processing of the respective mRNA. Using the digitonin-permeabilized cell import assay we demonstrate that H1(0) is transported into the nucleus in an energy- and temperature-dependent manner. In competition experiments we show that the transport of H1(0) from the cytoplasm into the nucleus is competed by the SV40 T-antigen-NLS-peptide coupled to HSA, an established substrate of the importin pathway. In transfection studies we have expressed in HeLa cells a series of plasmid constructs containing different fragments of the coding region of the H1(0) histone gene that were fused to the beta-galactosidase gene, and we have determined the subcellular localization of each fusion protein. The results show that H1(0) contains multiple transport-competent sequence elements that can function as NLS and that H1(0) meets the requirements for a transport into the nucleus by an importin-dependent pathway.
Collapse
Affiliation(s)
- K Schwamborn
- Department of Molecular Biology, University of Goettingen, Goettingen, D-37073, Germany
| | | | | |
Collapse
|
34
|
Suckow M, Schwamborn K, Kisters-Woike B, von Wilcken-Bergmann B, Müller-Hill B. Replacement of invariant bZip residues within the basic region of the yeast transcriptional activator GCN4 can change its DNA binding specificity. Nucleic Acids Res 1994; 22:4395-404. [PMID: 7971270 PMCID: PMC308472 DOI: 10.1093/nar/22.21.4395] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Abstract
Two residues are invariant in all bZip basic regions: asparagine -18 and arginine -10 (we define the first leucine of the leucine zipper of GCN4 as +1). X-ray structures of two specific GCN4-DNA complexes (Ellenberger et al., Cell, 71, 1223-1237, 1992; König & Richmond, J. Mol. Biol., 233, 139-154, 1993) demonstrate the involvement of both residues in specific base pair recognition. We replaced either asparagine -18 or arginine -10 with all other amino acids and tested the DNA binding properties of the resulting mutant peptides by gel mobility shift assays. Peptides with histidine -18 or tyrosine -10 bind with changed specificities to variants of the ATF/CREB site 5'A4T3G2A1C0*G0'T1'C2'A3'T4'3' with symmetric exchanges in positions 2/2' or 0/0', respectively. The double mutant with histidine -18 and tyrosine -10 combines the features of the parental single mutants and binds specifically to the respective double exchange target. Furthermore, the tyrosine -10 mutant clearly prefers the palindrome 5'ATGATATCAT3' over the corresponding pseudo-palindrome 5'ATGATTCA-T3', whereas the lysine -10 mutant binds better to the pseudo-palindromic AP1 site 5'ATGACTCAT3' than to the palindromic ATF/CREB site. Thus, although invariant within natural bZip proteins, asparagine -18 or arginine -10 can be functionally replaced by other amino acids, and their replacement can lead to new DNA binding specificities.
Collapse
Affiliation(s)
- M Suckow
- Institut für Genetik der Universität zu Köln, Germany
| | | | | | | | | |
Collapse
|